Rebel Medicine, a clinical‑stage biotechnology company developing innovative drug delivery systems and non‑opioid pain therapeutics for acute and post-operative pain, announced the closing of its $6 million Series A funding.
The Series A funding was led by Crocker Ventures with participation from Central Texas Angel Network (CTAN), Prosperity Solutions Capital, Utah Innovation Fund, SK Hart, the Joan & Tim Fenton Fund, Cantina Angels, and a syndicate of experienced life‑science angel investors.
This financial milestone coincides with the formal submission of its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Alevatrix, its lead non-opioid pain drug candidate.
How the funding will be used: The proceeds will fund a first-in-human, randomized, dose-escalation, active-controlled Phase 2 clinical trial in bunionectomy patients to assess the safety and efficacy of Alevatrix.
KEY QUOTE:
“This is a transformative moment for Rebel Medicine. The successful Series A fundraise validates our vision and the potential of our technologies. Coupled with IND clearance for Alevatrix, it enables us to accelerate clinical development of Alevatrix and bring our opioid-sparing pain therapies to patients faster.”
Brett Davis, PhD, Co-Founder and CEO of Rebel Medicine
